IN8bio Advances Cancer Therapies Amid Financial Restructuring

TipRanksNov 14 12:43

IN8bio Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 13 22:05 · Ratings

IN8bio Analyst Ratings

BenzingaNov 13 21:53 · Ratings

Express News | IN8bio, Inc. : H.c. Wainwright Cuts Target Price to $8 From $12.5

BreakingsNov 13 19:07

In8bio | 10-Q: Q3 2024 Earnings Report

SECNov 13 05:40 · Announcements

Express News | IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

BreakingsNov 13 05:26